Circulating tumour DNA (ctDNA) is an attractive tool in cancer research, offering many advantages over tissue samples obtained using traditional biopsy methods. There has been increasing interest in its application to muscle-invasive bladder cancer (MIBC), which is recognised to be a heterogeneous disease with overall poor prognosis. Using a range of platforms, studies have shown that ctDNA is detectable in MIBC and may be a useful biomarker in monitoring disease status and guiding treatment decisions in MIBC patients. Currently, with no such predictive or prognostic biomarkers in clinical practice to guide treatment strategy, there is a real unmet need for a personalised medicine approach in MIBC, and ctDNA offers an exciting avenue through which to pursue this goal. In this article, we present an overview of work to date on ctDNA in MIBC, and discuss the inherent challenges present as well as the potential future clinical applications.
International journal of molecular sciences. 2018 Aug 29*** epublish ***
Melissa P Tan, Gerhardt Attard, Robert A Huddart
Division of Radiotherapy & Imaging, Institute of Cancer Research, 15 Cotswold Road, Sutton, Surrey SM2 5NG, UK. ., Research Department of Oncology, UCL Cancer Institute, University College London, 72 Huntley Street, London WC1E 6DD, UK. ., Division of Radiotherapy & Imaging, Institute of Cancer Research, 15 Cotswold Road, Sutton, Surrey SM2 5NG, UK. .